“Context” was the word Delaware Supreme Court Chief Justice Collins J. Seitz Jr. used most often Wednesday during argument over the Zimmer Biomet Holdings Inc. derivative case that was dismissed last year.

Much of the argument from the medical device company shareholders’ attorney, Richard Speirs of Cohen Milstein Sellers & Toll, centered on allegations that Zimmer’s officers and directors knew of FDA compliance issues but failed to disclose them, resulting in an insider knowledge stock dump totaling $3.3 billion.